|
OmniComm Systems Announces Acquisition of EDC Business of eResearchTechnology
-- Acquisition Extends the Company’s Suite of Products and Increases
Breadth of EDC Customers --
FORT LAUDERDALE, Fla. and PHILADELPHIA, June 23 /PRNewswire-FirstCall/ --
OmniComm Systems, Inc. ® (OTC Bulletin Board: OMCM) ("OmniComm") a leader
in integrated electronic data capture (EDC) solutions for clinical trials,
and eResearchTechnology, Inc. (Nasdaq: ERES) ("ERT"), a global provider of
technology and services that enable the pharmaceutical, biotechnology, and
medical device industries worldwide to collect, interpret, and distribute
cardiac safety and clinical data, today announced that OmniComm has
acquired the EDC business of ERT.
"We believe strongly in the long-term growth of the EDC and eClinical
markets. We have positioned ourselves to be a leading provider of EDC
solutions and expect this transaction to allow us to grow more rapidly.
By combining the two EDC businesses, OmniComm extends and deepens its
roster of EDC customers and gains several key technologies that can be
added to the TrialMaster® eClinical suite of applications," stated
Cornelis F. Wit, CEO of OmniComm Systems. "We believe that we will be
able to leverage our existing EDC infrastructure and expertise to further
penetrate the combined portfolio of customers."
Mr. Wit continued, "the eClinical industry is going through a period of
consolidation and we believe that only those firms that can combine
superior products and services along with a demonstrated ability to
deliver a broad array of solutions will be able to effectively compete.
We are dedicated to broadening the products and services we offer and
developing as diverse a client base as possible. Our expansion into
Europe during 2007-2008 was the first prong of executing on this strategy.
ERT has served several markets, including the governmental sector and
Fortune 500 sponsors, that complement our focus on biotech and medical
device clinical trial sponsors."
Dr. Michael McKelvey, ERT’s President and CEO, commented "We have been
involved with our EDC business for many years and have a loyal customer
and employee base. However, it is clear that a more significant and
focused investment is required to be successful in today’s EDC market. We
are pleased to work with OmniComm to transition our customers and staff to
their organization. We will continue to expand our core cardiac safety and
ePRO business lines."
Revenues of the ERT EDC business were $5.9 million in the year ended
December 31, 2008 and $1.4 million in the three months ended March 31,
2009. ERT anticipates that the sale, excluding any impact of one-time
charges related to the sale, will not affect the Company’s previouslyissued
2009 fiscal year guidance. Under the terms of the transaction,
OmniComm issued 8.1 million shares of common stock and assumed certain
liabilities including deferred revenue relating to ERT’s EDC business in
exchange for the EDC assets of ERT which primarily include its EDC
software, applications and fixed assets and $1.15 million in cash paid by
ERT. OmniComm will be opening a new branch office in the New Jersey area
and will be transitioning the majority of the ERT eClinical support team
to this new office to provide on-going support and maintenance to the ERT
customers it acquires.
About OmniComm
OmniComm Systems, Inc. (www.OmniComm.com) provides customer-driven
Internet solutions to pharmaceutical, biotechnology, research and medical
device organizations that conduct life changing clinical trial research.
OmniComm's growing base of satisfied customers is a direct result of the
company's commitment to deliver products and services that ensure ease of
use, faster study build, ease of integration and better performance.
OmniComm's client intuitive pricing model allows companies that range from
small, to mid-size to large scale institutions to safely and efficiently
capitalize on their clinical research investments. OmniComm Systems, Inc.
has corporate headquarters in Ft. Lauderdale, Florida with offices in
Bonn, Chicago, Germany, Tula, Russia, California, New York, New Jersey,
North Carolina, Tennessee, Massachusetts and Georgia.
About eResearchTechnology, Inc. (ERT)
Based in Philadelphia, PA, ERT (eResearchTechnology, Inc.)
(www.ert.com) is a provider of cardiac safety and ePRO technology
and services to the global biopharmaceutical and medical device
industries. The Company is the market leader in providing centralized
core-diagnostic electrocardiographic (ECG) technology and services to
evaluate cardiac safety in clinical development.
Safe Harbor Disclaimer
Statements about OmniComm's future expectations, including without
limitation, future revenues and earnings, plans and objectives for the
future operations, future agreements, future economic performance,
operations and all other statements in this press release other than
historical facts are "forward-looking statements" within the meaning of
Section 27A of the Securities Act of 1933, Section 21E of the Securities
Exchange Act of 1934, and as that term is defined in the Private
Securities Litigation Reform Act of 1995. OmniComm intends that such
forward-looking statements be subject to the Safe Harbors created thereby.
Since these statements involve risks and uncertainties, including but not
limited to economic competitive, governmental, contractual and
technological factors affecting OmniComm's operations, markets and
profitability, actual results could differ materially and adversely from
the expected results.
Statements made by ERT included in this release may constitute forwardlooking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Such statements involve a number of risks and
uncertainties such as the Company's ability to obtain new contracts and
accurately estimate net revenues due to uncertain regulatory guidance,
variability in size, scope and duration of projects, and internal issues
at the sponsoring client, integration of acquisitions, competitive
factors, technological development, and market demand. As a result, actual
results may differ materially from any financial outlooks stated herein.
Further information on potential factors that could affect the Company's
financial results can be found in the Company's Reports on Form 10-K and
10-Q filed with the Securities and Exchange Commission. The Company
undertakes no obligation to publicly update any forward-looking statement,
whether as a result of new information, future events, or otherwise.
CONTACT:
Ronald Linares +1-954-473-1254, rtlcfo@omnicomm.com
and Keith Schneck, +1-215-282-5566, kschneck@ert.com
Back |
